The Epodure Biopump technology developed by AIM-listed Israeli firm Medgenics has been used to treat a second wave of anaemia patients in an ongoing phase I/II clinical trial. The technology uses patients' own tissue to manufacture and deliver a therapeutic protein – in this ...
Please Login to read the full article.
